CommentClinical validity of CSF biomarkers for Alzheimer's disease: necessary indeed, but sufficient?
References (12)
- et al.
Worldwide Alzheimer's Disease Neuroimaging Initiative
Alzheimers Dement
(2012) - et al.
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis
Lancet Neurol
(2016) - et al.
Amyloid biomarkers in Alzheimer's disease
Trends Pharmacol Sci
(2015) - et al.
Alzheimer's Disease
Lancet Neurol
(2016) - et al.
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
N Engl J Med
(2012) - et al.
Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia
Arch Gen Psychiatry
(2012)
Cited by (8)
Depression in neurodegenerative diseases: Common mechanisms and current treatment options
2019, Neuroscience and Biobehavioral ReviewsCitation Excerpt :At the neuropathological level, AD is characterized by extracellular deposits of amyloid-β (Aβ) plaques (which result from abnormal breakdown of amyloid precursor protein; APP) and intracellular accumulation of neurofibrillary tangles containing hyperphosphorylated tau protein (Glass et al., 2010; Olsson et al., 2016 Olsson et al., 2016). Of note, cerebrospinal fluid (CSF) levels of tau protein and Aβ show a predictable trend in AD patients, highlighting their use as potential biomarkers to predict onset and progression of this disease (Frisoni and Hansson, 2016; Olsson et al., 2016). Although neurodegeneration in the AD brain is not confined to a discrete neuronal population, cholinergic and γ-aminobutiric acid (GABA)ergic neurons are thought to be particularly vulnerable to this neurodegenerative process (Glass et al., 2010).
Serum Protein-Based Profiles for the Diagnostic Model of Alzheimer’s Disease
2023, American Journal of Alzheimer's Disease and other DementiasCCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment
2020, Alzheimer's and Dementia: Translational Research and Clinical InterventionsPlasma levels of soluble AβPPβ as a biomarker for Alzheimer's disease with dementia
2019, Journal of Alzheimer's DiseaseCerebrospinal fluid BACE1 activity and Saβppβ as biomarker candidates of alzheimer's disease
2018, Dementia and Geriatric Cognitive Disorders